Huober, Jens
van Mackelenbergh, Marion http://orcid.org/0000-0002-1084-5897
Schneeweiss, Andreas
Seither, Fenja
Blohmer, Jens-Uwe
Denkert, Carsten http://orcid.org/0000-0002-2249-0982
Tesch, Hans
Hanusch, Claus
Salat, Christoph
Rhiem, Kerstin
Solbach, Christine
Fasching, Peter A. http://orcid.org/0000-0003-4885-8471
Jackisch, Christian http://orcid.org/0000-0001-8537-3743
Reinisch, Mattea http://orcid.org/0000-0002-1381-8595
Lederer, Bianca
Mehta, Keyur
Link, Theresa
Nekljudova, Valentina
Loibl, Sibylle http://orcid.org/0000-0001-6488-4958
Untch, Michael
Article History
Received: 9 November 2022
Accepted: 13 March 2023
First Online: 7 April 2023
Competing interests
: J.H. reports receiving speakers honoraria from Lilly, Novartis, Roche, Pfizer, AstraZeneca, MSD, Celgene, and Eisai, travel expenses from Roche, Pfizer, Novartis, Celgene, and Daiichi, consulting fees from Lilly, Novartis, Roche, Pfizer, Hexal, AstraZeneca, MSD, and Celgene, and research grants from Celgene and Novartis. M.v.M. reports receiving honoraria from Amgen, AstraZeneca, Daiichi Sankyo, GenomicHealth, Gilead, GSK, Lilly, Molecular Health, Mylan, Novartis, Pfizer, PierreFabre, Roche, Seagen, travel expenses from Lilly, Gilead and Daiichi Sankyo. A.S. reports receiving honoraria from Roche, Celgene, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, and Lilly, research funding from Celgene, Roche, AbbVie, and Molecular Partner, expert testimony from Roche and AstraZeneca, and travel expenses from Celgene and Roche. J.-U.B. reports receiving honoraria from Amgen, AstraZeneca, GenomicHealth, MSD Oncology, Myriad Genetics, Novartis, Pfizer, Roche, and Sonoscape. C.D. was a cofounder and shareholder of Sividon Diagnostics (now Myriad), he reports receiving speakers honoraria and travel support from Teva, Celgene, Roche, Pfizer, Novartis, Astra Zeneca, he is a consultant for MSD and Daichii Sankyo and an inventor on patent EP18209672 and patent EP20150702464. H.T. reports receiving honoraria and consulting fees from Pfizer, Novartis, Roche, Lilly, and AstraZeneca, and travel expenses from Pfizer, and Lilly. C.H. reports receiving consulting fees from Roche, Novartis, Pfizer, AstraZeneca, Celgene, and Lilly Pharma. K.R. reports receiving honoraria from AstraZeneca, Pfizer, Tesaro, and Roche, consulting fees from Tesaro and Pfizer, and travel expenses from Pfizer, Tesaro, and Roche. CSo reports personal fees and non-financial support from Olympus Europa, MYLAN, and Medtronic, and personal fees from Roche, Pfizer, and AstraZeneca. P.A.F. reported grants from Novartis, Biontech, Novartis, Roche, Pfizer, Celgene, Daiichi-Sankyo, Teva, Astra Zeneca, Merck Sharp and Dohme, Myelo Therapeutics, Macrogenics, Eisai, Puma, and Cepheid. C.J. reports receiving honoraria from Roche, Sanofi Aventis, AstraZeneca, and Novartis, consulting fees from Roche and Celgene, and travel expenses from Roche, AstraZeneca, and Novartis. T.L. reports receiving honoraria from Pfizer, Novartis, TEVA, Tesaro, MSD, Roche, and Amgen, consulting fees from Amgen, Roche, Tesaro, and travel expenses from Daiichi Sankyo, Pharma Mar, Roche, and Pfizer. S.L. reported grants and honoraria to institution from Abbvie, Amgen, AstraZeneca, BMS, Celgene, Cepheid, Immunomedics, Myriad Genetics, Novartis, Lilly, MSD, Pfizer, Roche, and Daiichi Sankyo, and patent EP14153692.0. M.U. reports receiving honoraria to institution from Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Lilly, MSD Merck, Mundipharma, Myriad Genetics, Novartis, Pfizer, PUMA, Roche, Sanofi Aventis, and TEVA, and consulting fees from Abbvie, Amgen, AstraZeneca, Celgene, Lilly, Daiichi Sankyo, MSD, Novartis, Odonate, Pfizer, PUMA, Roche, and Sanofi Aventis. F.S., B.L., K.M. and V.N. declares to be GBG Forschungs GmbH employee. GBG Forschungs GmbH received funding for research grants from Abbvie, AstraZeneca, BMS, Daiichi-Sankyo, Gilead, Novartis, Pfizer and Roche (paid to the institution); other (non-financial/medical writing) from Daiichi-Sankyo, Gilead, Novartis, Pfizer, Roche and Seagen (paid to the institution). GBG Forschungs GmbH has following royalties/patents: EP14153692.0, EP21152186.9, EP15702464.7, EP19808852.8 and VM Scope GmbH. All other authors declare no competing interests.